On February 23, 2023, a New Jersey federal judge granted preliminary approval of a $40 million settlement in Odeh v. Immunomedics, Inc., No. 2:18-cv-17645 (D. N.J.). The lawsuit alleged that Defendants made materially false and misleading statements and omissions about Immunomedics’ receipt of and approach to handling a Form 483 from the Food and Drug Administration, which ultimately caused the Company’s new drug application to fail.
Gregg Edwards was retained by co-lead counsel Block & Leviton and Robbins, Geller, Rudman & Dowd LLP to provide expert opinions and testimony regarding market efficiency, price impact, and class-wide damages for Immunomedics’ common stock.
